Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
CYD-TDV
VCD
dengue
serostatus
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
01
06
2020
pubmed:
7
4
2021
medline:
8
10
2021
entrez:
6
4
2021
Statut:
ppublish
Résumé
CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516.
Sections du résumé
BACKGROUND
CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57).
METHODS
The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection.
RESULTS
In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups.
CONCLUSIONS
CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516.
Identifiants
pubmed: 33822015
pii: 6210060
doi: 10.1093/cid/ciab288
pmc: PMC8442794
doi:
Substances chimiques
Antibodies, Viral
0
Dengue Vaccines
0
Vaccines, Attenuated
0
Vaccines, Combined
0
Banques de données
ClinicalTrials.gov
['NCT00842530', 'NCT01983553', 'NCT01374516', 'NCT01373281']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1012Subventions
Organisme : Sanofi Pasteur
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet. 2014 Oct 11;384(9951):1358-65
pubmed: 25018116
Curr Top Microbiol Immunol. 2010;338:57-66
pubmed: 19802578
J Virol Methods. 2018 Jul;257:62-68
pubmed: 29684416
N Engl J Med. 2015 Jan 8;372(2):113-23
pubmed: 25365753
Am J Trop Med Hyg. 2019 Jul;101(1):164-179
pubmed: 31115304
Vaccine. 2020 Apr 23;38(19):3531-3536
pubmed: 32204943
Am J Trop Med Hyg. 2011 Jan;84(1):127-34
pubmed: 21212214
PLoS Negl Trop Dis. 2016 Jul 14;10(7):e0004821
pubmed: 27414655
Clin Microbiol Infect. 2018 Jul;24(7):755-763
pubmed: 29408333
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
Hum Vaccin Immunother. 2017 Sep 2;13(9):2004-2016
pubmed: 28598256
J Infect Dis. 2004 Aug 15;190(4):810-8
pubmed: 15272410
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
J Infect Dis. 2018 Feb 14;217(5):742-753
pubmed: 29194547
Lancet. 2012 Nov 3;380(9853):1559-67
pubmed: 22975340
N Engl J Med. 2015 Sep 24;373(13):1195-206
pubmed: 26214039
J Clin Virol. 2009 Oct;46 Suppl 2:S7-9
pubmed: 19800564